In this study, we investigated the predictive or prognostic role of KRAS and TP53 in CRC treated with anti-PD-1 or anti-PD-L1 therapy and its correlation with PD-L1 expression in CRC. This evidence concerns the gene KRAS and colorectal carcinoma.